Clinical Trial Update: A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 double-blind trial evaluating BAY 1142524 for efficacy and safety after acute myocardial infarction with left ventricular dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Left Ventricular Dysfunction
• Myocardial Infarction

Drugs mentioned

• BAY 1142524

Snippet

Sponsor: Bayer | Conditions: Myocardial Infarction | Phase 2 | Status: COMPLETED